0001797336 false 0001797336 2023-01-13 2023-01-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

January 13, 2023

Date of Report (Date of earliest event reported)

 

 

 

AYALA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-39279   82-3578375
(State or Other Jurisdiction
of Incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

Oppenheimer 4

Rehovot, Israel 7670104

(Address of Principal Executive Offices) (Zip Code)

 

(857) 444-0553

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.01 par value per share AYLA The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On January 13, 2023, Ayala Pharmaceuticals, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Meeting”). A total of 9,408,088 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), were present in person or represented by proxy at the Meeting, representing approximately 63.47% percent of the Company’s outstanding Common Stock as of the December 7, 2022 record date. The following are the voting results for the proposals considered and voted upon at the Meeting, each of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on December 12, 2022.

 

Item 1 — Adoption of the Agreement and Plan of Merger (the “Merger Agreement”), dated October 18, 2022, by and among the Company, Advaxis, Inc. (“Advaxis”) and Doe Merger Sub, Inc. (“Merger Sub”), pursuant to which, among other things, Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Advaxis.

 

Votes FOR   Votes AGAINST   Votes ABSTAINED
9,382,563   24,310   1,215

 

Item 2 — Approval of the adjournment of the Meeting from time to time, if necessary or appropriate, to solicit additional affirmative votes in favor of the Merger Agreement if there are insufficient votes at the time of such adjournment to approve the Merger Agreement.

 

Votes FOR   Votes AGAINST   Votes ABSTAINED
9,358,455   37,698   11,935

 

Based on the foregoing votes, Item 1 and Item 2 were approved. 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 13, 2023 AYALA PHARMACEUTICALS, INC.
     
  By: /s/ Roni Mamluk
    Roni Mamluk, Ph.D.
    Chief Executive Officer and President

 

 

 

Ayala Pharmaceuticals (NASDAQ:AYLA)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Ayala Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Ayala Pharmaceuticals (NASDAQ:AYLA)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Ayala Pharmaceuticals 차트를 더 보려면 여기를 클릭.